[go: up one dir, main page]

WO2007076127A3 - Modulateurs du facteur de croissance transformant - Google Patents

Modulateurs du facteur de croissance transformant Download PDF

Info

Publication number
WO2007076127A3
WO2007076127A3 PCT/US2006/049271 US2006049271W WO2007076127A3 WO 2007076127 A3 WO2007076127 A3 WO 2007076127A3 US 2006049271 W US2006049271 W US 2006049271W WO 2007076127 A3 WO2007076127 A3 WO 2007076127A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
transforming growth
pyrazoles
factor modulators
condensed imidazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/049271
Other languages
English (en)
Other versions
WO2007076127A2 (fr
Inventor
Wen-Cherng Lee
Claudio Chuaqui
Lihong Sun
Michael Hoemann
Deqiang Niu
Dingxue Yan
Dominique Bonafoux
Mark Cornebise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Priority to EP06848155A priority Critical patent/EP1973909A2/fr
Publication of WO2007076127A2 publication Critical patent/WO2007076127A2/fr
Publication of WO2007076127A3 publication Critical patent/WO2007076127A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des composés qui sont des modulateurs du facteur de croissance transformant β (TGF β) et qui sont utilisés pour traiter des maladies associées au TGF β.
PCT/US2006/049271 2005-12-22 2006-12-22 Modulateurs du facteur de croissance transformant Ceased WO2007076127A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06848155A EP1973909A2 (fr) 2005-12-22 2006-12-22 Modulateurs du facteur de croissance transformant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75302305P 2005-12-22 2005-12-22
US60/753,023 2005-12-22

Publications (2)

Publication Number Publication Date
WO2007076127A2 WO2007076127A2 (fr) 2007-07-05
WO2007076127A3 true WO2007076127A3 (fr) 2007-08-02

Family

ID=38024224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049271 Ceased WO2007076127A2 (fr) 2005-12-22 2006-12-22 Modulateurs du facteur de croissance transformant

Country Status (2)

Country Link
EP (1) EP1973909A2 (fr)
WO (1) WO2007076127A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314617B1 (fr) 2004-07-23 2015-06-24 Acceleron Pharma Inc. Polypeptides du récepteur ActRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA015105B1 (ru) 2005-11-23 2011-06-30 Акселерон Фарма Инк. Антагонисты активина - actriia и их применение для стимулирования роста кости
CN107050424A (zh) 2007-02-01 2017-08-18 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW202104248A (zh) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2481415B1 (fr) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Compositions comprenant des antagonistes Activin-ActRIIA
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
EP2300466B1 (fr) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Composés d'imidazopyridine et d'imidazopyrazine utilisés comme inhibiteurs de kinase
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010083034A1 (fr) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Procédés permettant d'augmenter l'adiponectine
CA2764890A1 (fr) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Procede visant a augmenter le nombre d'adipocytes thermogenes
MX387164B (es) 2009-06-12 2025-03-19 Acceleron Pharma Inc Proteínas de fusión actriib-fc truncadas.
EP3818988A1 (fr) * 2009-11-03 2021-05-12 Acceleron Pharma Inc. Procédés de traitement de la maladie du foie gras
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
EP2763986B1 (fr) * 2011-09-22 2017-06-07 Merck Sharp & Dohme B.V. Antagonistes du récepteur de la fsh
EP3308796B1 (fr) 2012-11-02 2021-07-14 Celgene Corporation Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
RU2672722C2 (ru) * 2014-04-10 2018-11-19 Хубэй Био-Фармасьютикал Индастриал Текнолоджикал Инститьют Инк. Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
EP3357925B1 (fr) * 2015-09-30 2021-10-27 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Composé 4h-pyrazolo-[1,5-alpha]-benzimidazole de type sel et de type cristal, son procédé de préparation et son intermédiaire
PT3470409T (pt) 2016-06-13 2020-05-11 Genfleet Therapeutics Shanghai Inc Composto de amida alfa e beta insaturada derivado de benzotriazol utilizado como inibidor de tgf-beta ri
AU2023320651A1 (en) * 2022-08-08 2025-02-27 Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. TGF-β INHIBITOR COMPOUND AND USE THEREOF
CN117700413A (zh) * 2024-02-05 2024-03-15 湖南工程学院 一种六氢咪唑并[2,1-a]异喹啉衍生物及其合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094833A1 (fr) * 2001-05-24 2002-11-28 Eli Lilly And Company Derives de pyrrole utilises comme agents pharmaceutiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094833A1 (fr) * 2001-05-24 2002-11-28 Eli Lilly And Company Derives de pyrrole utilises comme agents pharmaceutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CALLAHAN J F ET AL: "Identification of Novel Inhibitors of the Transforming Growth Factor .beta.1 (TGF-.beta.1) Type 1 Receptor (ALK5)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 5, 30 January 2002 (2002-01-30), pages 999 - 1001, XP002293066 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels

Also Published As

Publication number Publication date
WO2007076127A2 (fr) 2007-07-05
EP1973909A2 (fr) 2008-10-01

Similar Documents

Publication Publication Date Title
WO2007076127A3 (fr) Modulateurs du facteur de croissance transformant
MX2008008152A (es) Compuestos heterociclicos biciclicos.
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2004080377A3 (fr) Nouveaux composes modulant le canal kcnq et leur utilisation
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007085895A3 (fr) Inhibiteurs fap
WO2009077443A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2008029096A8 (fr) Composés d'activation de p53
WO2011117145A3 (fr) Inhibiteurs de pyrrolopyrazine kinase
WO2009156462A3 (fr) Composés organiques
GEP20125643B (en) Aurora kinase modulators and method of using same
WO2009077500A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009000442A8 (fr) Procedes de preparation de pyrazoles
WO2008113559A3 (fr) Indolizines et dérivés analogues aza de celles-ci en tant que composés actifs sur le système nerveux central
WO2008149353A3 (fr) Composés activant la télomérase et leurs procédés d'utilisation
AU2007249926A8 (en) Monocyclic heteroaryl compounds
MX2010003368A (es) Derivados de imidazol.
MX2009007231A (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de la fosfodiesterasa 4.
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2008061108A3 (fr) Dérivés de phtalazine
WO2009030224A3 (fr) Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale
GB0508318D0 (en) Organic compounds
WO2007072201A3 (fr) 3-aminocyclopentanecarboxamides en tant que modulateurs de recepteurs de chimiokine
GB0508314D0 (en) Organic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006848155

Country of ref document: EP